Tuesday, 9 June 2020

Global Overactive Bladder Treatment Market Positive Growth And Forecasts By 2023

Market Scenario:
Overactive bladder is a condition that occurs in various diseases such as Parkinson's disease, multiple sclerosis, stroke, and others. Rise in prevalence of these diseases and rapid increase in the global geriatric population are inducing high demand for effective treatment of overactive bladder, which in turn is propelling the growth of the global overactive bladder treatment market. Increased marketing activities, availability of affordable treatments and development of innovative treatment procedures are also fueling the growth of the global overactive bladder treatment market. However, low penetration of treatment options in the healthcare sector and lack of awareness among the population of the underdeveloped countries are restricting the expansion of the global overactive bladder treatment market analysis during the assessment period.
The global overactive bladder treatment market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global overactive bladder treatment market growth is expected to register a CAGR of ~ 3.1% during the forecast period of 2018–2023.
Despite the drivers, lack of awareness in developing countries and undesired systemic effects of some current treatment options may hinder the growth of the market during the assessment period.
Company Profiles    
  • Astellas Pharma Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical
  • Allergan, Plc. 
  • Mylan N.V. 
  • Endo International Plc 
  • Hisamitsu Pharmaceutical Co., Inc.
  • Sanofi S. A.
  • Aurobindo Pharma Limited 
  • Johnson & Johnson
  • Intas Pharmaceuticals Ltd. 
  • Apotex Inc. 
  • Macleods Pharmaceuticals Ltd. 
  • Medtronic PLC
  • Cogentix Medical, Inc.
  • Others
Segmentation
The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease.
On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.
The global overactive bladder treatment market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.
On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and overactive bladder in other disorders.
Geographically, the global overactive bladder treatment market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The overactive bladder treatment market in the Americas is further segmented into North America and South America. North America is further classified as the US and Canada.
The overactive bladder treatment market in Europe is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.
The overactive bladder treatment market in Asia-Pacific is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia-Pacific.
The overactive bladder treatment market in the Middle East and Africa is segmented into the Middle East and Africa.
Regional Market Summary
The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is anticipated to dominate the market in the Americas owing to the increasing geriatric population, growing occurrences of OAB, and the availability of numerous healthcare coverage systems such as Medicare.
Europe is anticipated to hold the second position in the global overactive bladder treatment market. It is estimated that the market growth in this region is attributed to the rising incidences of OAB and availability of reimbursement for certain treatment options. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) provides reimbursement for the Botox therapy.
The overactive bladder treatment market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of bladder overactivity, rising geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition.
The Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market. In this region, the Middle East is expected to dominate owing to the rising healthcare expenditure and rising occurrences of neurological diseases, especially among the aged population.
Posted by at No comments:

Monday, 8 June 2020

Tele-Intensive Care Unit (ICU) Market 2019 - Shares, Revenue, Analysis And Forecasts Till 2024

Tele-Intensive Care Unit (ICU) Market Scenario

Tele-Intensive Care Units (ICU) are advanced systems used for the treatment of critically ill patients by using off-site clinical resources. It is a part of telemedicine which is used for the exchange of medical information for conducting various medical activities such as monitoring, treatment, and rehabilitation.
The Global Tele-Intensive Care Unit (ICU) Market Size is accounted for USD 1820 Million in 2018 and expected to register 16.4% CAGR during the forecast period (2019–2024).
The rising prevalence of chronic disorders such as cancer, increasing geriatric population, technological advancements in the healthcare sector and increasing cases of patients affected by neurological disorders across the world are expected to drive the growth of the market. For instance, according to the Centers for Disease Control and Prevention (CDC), In the year 2016, more than 10.4 million cases of tuberculosis were registered in the world, and 1.7 million deaths occurred due to tuberculosis in the year 2016. Moreover, rising R&D spending and aggressive strategies adopted by the top players, such as new product launches, are contributing to the growth of the market.
The lack of adequate reimbursement policy and high costs involved in the establishment of these centers may hamper the growth of the market during the assessment period.

Tele-Intensive Care Unit (ICU) Market Segmentation

The global Tele-Intensive Care Unit (ICU) market has been segmented on the basis of component and type of management.
On the basis of component, the market has been classified as hardware and software. The market, by hardware, has been further segmented into the computer system, communication lines, physiological monitors, therapeutic devices, video feeds, and others.
Based on the type of management, the market has been segmented into intensivist, open, co-managed, open with a consultant, and other types of management.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Tele-Intensive Care Unit (ICU) market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European Tele-Intensive Care Unit (ICU) market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The Tele-Intensive Care Unit (ICU) market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Tele-Intensive Care Unit (ICU) market in the Middle East & Africa has been segmented into the Middle East and Africa.

Tele-Intensive Care Unit (ICU) Market Company Profiles

  • SOC Telemed
  • Intouch Technologies, Inc.
  • Koninklijke Philips N.V.
  • Advanced Icu Care
  • UPMC
  • Banner Health
  • Teleicucare
  • Eagle Telemedicine
  • Apollo TeleHealth Services
  • Inteleicu
  • Others
Tele-Intensive Care Unit (ICU) Regional Market Summary
The Americas are likely to dominate the global Tele-Intensive Care Unit (ICU) market owing to the technological advancements related to healthcare in the region, the surge in cases of chronic disorders, and an increasing number of hospitals in the regions.  According to the report published by the American Hospital Association, more than 5200 community hospitals were present in the US in the year 2018, out of which 3,387 belongs to urban areas, and 1875 were from rural areas.
The European market is expected to be the second-largest Tele-Intensive Care Unit (ICU) market. The market growth in this region can be attributed to the increasing demand of healthcare systems which can provide real-time data, rising cases of neurological disorders in the European region, and government funding and support of the healthcare sector along with the increasing research and development. Moreover, favorable reimbursement policies in European countries are contributing to the growth of the market in this region. According to the European Academy of Neurology, neurological disorders are increasing in Europe, and in the year 2017, more than 220 million European population was affected by neurological complications.
Asia-Pacific is expected to be the fastest-growing Tele-Intensive Care Unit (ICU) market during the forecast period owing to the increasing geriatric population, rising investments in healthcare, and expansions by market players in the region. Also, countries such as India and China are considering the fastest growing region due to the presence of a huge patient population. Moreover, the government of these countries is open to adopting new technology and the best treatment option from a developed country.
The market in the Middle East & Africa is expected to account for the smallest share of the global Tele-Intensive Care Unit (ICU) market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Posted by at No comments:

Live Cell Encapsulation Market Expects An Extensive Growth In Roi Till 2023

The Global Live Cell Encapsulation Market is expected to grow significantly over the forecast period. It is estimated that the global live cell encapsulation market is expected to register a CAGR ~ 3.22% during the forecast period of 2018 to 2023, with an estimated market value of USD 249.87 million in 2017.
The global market is driven by factors such as rising demand for clinical efficacy of cell encapsulation technologies and growing awareness related to the clinical role of encapsulated cells to treat different chronic diseases. Additionally, encapsulation provides the durability and stability of the nutrient during handling and storage. Thus, such benefits of this technique are luring the competitors to enter the industry with new Live Cell Encapsulation Market Trends.
Browse Sample of the Report @
On the other hand, the lack of skilled technicians, ethical issues, and unaffordability of research organizations and small-scale companies in certain economies is restraining the growth of live cell encapsulation market. Moreover, the availability of high-quality raw material is also restraining the growth of the market. Nevertheless, changes in regulatory policies and rise in demand for effective therapies to treat complicated disorders is expected to reduce the impact of barriers over the forecast period.
Moreover, major companies in the market are involved in strategic collaborations to brace their position in the market. For instance, in August 2018, Balchem Italia S.r.l., a wholly owned subsidiary of Balchem Corporation, acquired Bioscreen Technologies, S.r.l., a privately held manufacturer of encapsulated and fermented feed nutrition ingredients. With this, the company aims to expand its position in the market.
Segmentation
The Global Live Cell Encapsulation Market has been segmented into manufacturing technique, polymer type, and application. The market, based on manufacturing technique, has been segmented into simple dripping, electrostatic dripping, coaxial airflow, rotating disk atomization, and others. The market, by polymer type, has been further segmented into alginate, HEMA-MMA, Chitosan, silica, cellulose sulfate, PAN-PVC, and others. The market, by application, has been segmented into drug delivery, regenerative medicine, cell transplantation, and others. The drug delivery segment is expected to hold a major share owing to the increasing use of live cell encapsulation techniques in drug delivery systems. The segment of regenerative medicine is expected to be the fastest growing segment due to the rising trend and benefits of encapsulation in the tissue engineering field.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The live cell encapsulation market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European live cell encapsulation market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The live cell encapsulation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The live cell encapsulation market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
Balchem Corporation, Evonik Industries, Merck KGaA, BÜCHI Labortechnik AG, Lycored, Blacktrace Holdings Ltd., Living Cell Technologies, Reed Pacific Pty Limited, MiKroCaps, Biotime, Inc., Neurotech Holdings, LLC, Sernova Corporation, Encapsys, LLC, Sigilon Therapeutics, Inc., and Viacyte, Inc. are some of the key players in the global live cell encapsulation market.
Regional Market Summary
Geographically, the Americas is expected to dominate the global live cell encapsulation market due to the increasing per capita healthcare expenditure, and the heavy adoption of new technology.
Furthermore, rising expenses in research and development by healthcare bodies and the government is anticipated to drive the growth of the market in this region. Apart from this, increasing applications of regenerative medicine in the US is expecting to push the growth of live cell encapsulation market. For instance, According to the National Institutes of Health (NIH), approximately 5,00,000 Americans benefit from a transplant each year.
Europe showed a considerable amount of growth in the global live cell encapsulation market. The market growth in this region is because of the presence of a well-established healthcare system and increase in chronic diseases. For instance, according to cancer research UK, there were approximately 9, 921 cases of cancer diagnosed in 2015. Such high rates of cancer are likely to increase demand for the use of next-generation sequencing as well as increase the market demands for monoclonal bodies and cellular research. These factors are expected to have a positive impact on the live cell encapsulation market.
Asia-Pacific is expected to have a sturdy growth rate during the forecast period owing to the huge patient pool of chronic diseases and government initiatives of healthcare reforms. However, less capital investment is restricting the market growth of this region.
On the other hand, the Middle East & Africa has the least share of the market due to the low disposable income. Moreover, the limited adoption of advanced healthcare facilities and limited access to treatment facilities is also expected to drive the growth of the market in the near future
Posted by at No comments:

Rectovaginal Fistula Market Leading Rectovaginal Fistula Market Key Developments Trends, Analysis And Forecasts Till 2023

Market Scenario
As per the Birth Injury Guide, estimates show that between 700 and 900 women die every year due to pregnancy or childbirth-related complications in United States.
Additionally, the growing research and development expenditure by the government as well as private sector is likely to contribute to the market growth. However, the high cost of surgery may restraint the market trends growth during the assessment period.  
Due to increasing focus on research and development in treatment of diseases, moreover increasing applications in cancer treatment are the factors responsible to boost the market growth during assessment period. Companies are using a Rectovaginal Fistula market trends of strategic alliance and acquisition to gain the market and minimize the competition in the market.
The Global Rectovaginal Fistula Market held a market value of USD 950 million in 2017 and is projected to grow at a CAGR of 5.4% over the forecast period. 
Key players
Some of the prominent players in the global rectovaginal fistula market are Cook Medical, Takeda Pharmaceutical Company, Johnson & Johnson Services Inc., Pfizer Inc., Allergan, AbbVie Inc, Novartis International AG, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A, and others
Segmentation
The global rectovaginal fistula market has been segmented into diagnosis, treatment, and end user.
Based on treatment, the market has been segmented into medications and surgery. Medications is further segmented into antibiotics and infliximab. Rectovaginal Fistula Surgery is further segmented into sewing an anal fistula plug or patch of biologic tissue into the fistula, using a tissue graft, repairing the anal sphincter muscles, performing a colostomy before repairing a fistula in complex or recurrent cases.
By diagnosis, the market has been segmented into physical exam, contrast tests, blue dye test, computerized tomography (CT) scan, magnetic resonance imaging (MRI), anorectal ultrasound, anorectal manometry, and others.
The rectovaginal fistula market, by end user, has been segmented into hospitals & clinics, diagnostic centres, academic institutions and research organizations, and others.
The global rectovaginal fistula market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rectovaginal fistula market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.         
The European rectovaginal fistula market has been segmented into Western Europe and Eastern Europe. The Western Europe rectovaginal fistula market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.      
The rectovaginal fistula market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rectovaginal fistula market in the Middle East & Africa has been segmented into the Middle East and Africa.       
Regional Market Summary
On regional basis, the Americas is anticipated to dominate the global rectovaginal fistula market owing to the growing R&D budgets by both government as well as commercial pharmaceutical and biotechnological companies and increasing adoption of advanced technologies in the region.  Europe is expected to hold the second largest position in the global rectovaginal fistula market owing to the presence of strong academic & research base and availability of funding for research in the European countries. Asia Pacific has served an opportunity for rectovaginal fistula market in this region due to increasing demand for the better treatment and devices and increasing prevalence of disease like cancer. The Middle East & Africa has the least share of the global rectovaginal fistula market. Moreover, the major market share of the region is expected to be held by the Middle East region owing to the increasing government initiatives for the healthcare sector.   
Posted by at No comments:

International Automatic Pill Dispenser Market 2019 Estimation And Forecasts Up To 2023

Automatic Pill Dispenser Market Highlights:
The Global Automatic Pill Dispenser Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 1,700 million in 2018 and is projected to register a CAGR of 7.3% over the forecast period.
The increasing prevalence of cardiovascular disorders and growing older population are the key factors driving the automatic pill dispenser machine market. As per the report published by the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults were dealing with at least one type of cardiovascular disease.
Various other factors such as the advancements in automatic pill dispenser, increasing geriatric population, untapped emerging markets, rise in regulatory approvals, and increasing investment on home care centers are also expected to propel the growth of the market.
However, the high cost of the system can hamper market growth over the forecast period.
Key Players:
Some of the key players in the global automatic pill dispenser market are Baxter International Inc, Becton, Dickinson and Company, Cerner Corporation, Capsa Healthcare, McKesson Corporation, Omnicell Inc., ScriptPro LLC, Swisslog Holdings AG, Yuyama Co.Ltd. Talyst, Inc., and others
Segmentation:
The global automatic pill dispenser market is segmented based on type, end user, and region.
The global market for automatic pill dispenser, by type, is segmented into a centralized, automated dispensing system, and decentralized the automated dispensing system. The centralized, automated dispensing system is further classified into robotic automated dispensing systems, and carousels. Furthermore, decentralized automated dispensing system is classified into a pharmacy-based automated dispensing system, ward-based automated dispensing system, and automated unit dose dispensing system.
Based on end user, the market is segmented into hospital pharmacy, retail pharmacy, and home healthcare.
In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.
The automatic pill dispenser market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European automatic pill dispenser market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The automatic pill dispenser market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The automatic pill dispenser market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Analysis:
The Americas dominated the global market for automatic pill dispenser owing to the rising geriatric population within the region. As per the data suggested by the United Census Bureau, by 2060, the US is projected to grow by 79 million people, from about 326 million today to 404 million. The population is projected to cross the 400-million threshold in 2058. Additionally, according to the WHO, in the US, more than 20% of the total population is likely to be aged 65 years or over by 2030. Rising participation of market players is also strongly impacting the growth of the Americas automatic pill dispenser market. Moreover, the rising prevalence of chronic disorders such as cardiovascular disorders, cancer, diabetes, and others are driving the growth of the market. For instance, according to the National Cancer Institute, in 2016, in the US, 15.5 million new cases of cancer were registered, and approximately USD 147.3 billion were spent for cancer care.
In 2018, it was estimated that Europe stood second in the global automatic pill dispenser market. Technological advancements, along with the availability of funding opportunities in research and innovation, will support market growth.
Asia-Pacific (APAC) is expected to represent the phenomenal market growth throughout the forecast period due to rising prevalence of chronic conditions, growing awareness about medications, and increasing healthcare expenditure. During 2016-2017, Australia spent nearly USD181 billion on health, which is more than USD 7,400 per person and 10% of overall economic activity.
On the other hand, the Middle East and Africa held the least share in the global automatic pill dispenser market due to the low economic development, especially within the African region.
Posted by at No comments:

ELISpot and FluoroSpot Assay Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2023

Market Scenario:
ELISpot and FluoroSpot assays are techniques which are used to assess the antibody reactivity at the cellular level. They are extensively used by hospitals as well as research institutes for early detection of various diseases, most commonly for tuberculosis or viral infection. FluoroSpot assay is an adaptation of the ELISpot assay and has gained widespread acceptance. Market Research Future (MRFR) has extensively studied the patterns and trends governing the global ELISpot and FluoroSpot assay market analysis forecast between 2018-2023 in a detailed report. MRFR has asserted that the market is likely to reach USD 287 Mn at a splendid CAGR of 16.2% over the forecast period. The market stood at USD 135 Mn in 2017.
ELISpot and FluoroSpot assays are outstandingly sensitive and are easy to perform due to which they find extensive application in research studies concerning vaccine development, allergies, cancer, and other research purposes. The surge in the incidence rate of chronic diseases has been instrumental in the growth of the market. Increasing disease burden necessitate the development of vaccines which induce demand for ELISpot and FluoroSpot assays. Additionally, the growing occurrence of oncological diseases has further boosted the market growth. ELISpot and FluoroSpot Market Trends and Technological advances in techniques have resulted in increased sensitivity, robustness, and ease of performance which has increased the adoption rate of these techniques. Other factors motivating growth within the market include an increase in a number of clinical trials and increasing healthcare expenditure across the globe. However, the growth of the market might be hindered by factors such as lack of techniques with adequate knowledge to perform these tests and the availability of alternative detection technologies.
Key players:
Some of the key players in the global ELISpot and FluoroSpot Assay market are Oxford Immunotec (UK), Cellular Technologies (US), Mabtech (Sweden), Becton, Dickinson and Company (US), and Abcam (UK)Bio-Techne (US), Autoimmun Diagnostika (Germany), Biotech Investissement (France), Lophius Biosciences (Germany), and U-CyTech (Netherlands), and Others.
Segmentation:
The Global ELISpot and FluoroSpot Assay Market is segmented on the basis of product, application, and end-user. The ELISpot and FluoroSpot Assay market, by product is categorised into various assay kit, analyzer, ancillary products. The assay kit is sub-segmented into T Cell assay and B Cell assay. On the basis of application, the market is segmented into transplant, vaccines development, clinical trials, cancer treatment. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centres, diagnostic centres, research centers, and others.
Regional Analysis:
Europe stood second largest in the ELISpot and FluoroSpot Assay market owing to the increasing number of pharmaceutical companies, rising in the development of innovative vaccines for the treatment of various viral diseases. The growing funding from government and private agencies for drug development also support the ELISpot and FluoroSpot Assay market in this region.  Asia-Pacific was estimated to be the fastest growing region for the global ELISpot and FluoroSpot Assay market in 2017. The market is expected to witness growth owing to the rising prevalence of viral infection, increasing geriatric population in this region and growing demand for ELISpot and FluoroSpot Assay in research field.
The Middle East and Africa holds the least share in the global ELISpot and FluoroSpot Assay market due to the presence of low health expenditure, lack of skilled technicians and less pharmaceutical company in this region. However, the market is expected to witness growth due to increasing research & development in the Middle East.
Posted by at No comments:

Cerebral Palsy Market Shares Analysis, Key Development Strategies And Forecasts Till 2023

Market Scenario
Cerebral palsy (CP) is a group of lifelong neurological disorders that affect movement and coordination, caused by damage to or abnormalities inside the developing brain of the infant. CP can occur before, during or soon after birth. Additionally, cerebral palsy can develop from several factors such as lack of oxygen to the brain, genetic conditions, brain infections, brain hemorrhage, chemical or substance abuse during pregnancy, injury to the head, and severe jaundice.
The global cerebral palsy market is driving owing to the growing prevalence of cerebral palsy coupled with increasing awareness about the condition. Moreover, the growing adoptions of medications for controlling the symptoms of the cerebral palsy are anticipated to propel the market growth. Additionally, increasing expenditure for the healthcare sector in developed economies and increasing insurance coverage contribute to the growth of the market.
Despite the drivers, side effects associated with medications and high treatment cost and lack of awareness in some developing regions may hamper the market growth during the assessment period.
Regional Summary
The Americas is expected to dominate the global cerebral palsy market during the forecast period owing to the well-established healthcare sector, growing awareness about CP, and the rising prevalence of cerebral palsy in the region. The European market is expected to be the second-largest market due to the growing healthcare expenditure and increasing prevalence of cerebral palsy. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to the developing healthcare infrastructure, and favorable government initiatives for the healthcare sector. The Middle East & Africa is likely to account for the least cerebral palsy market share over global market owing to the lack of economic development, especially in the African region.
Key players
Some of the prominent players in the global cerebral palsy market are Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc., Medtronic, Meridigen Biotech Co., Ltd., GW Pharmaceuticals Plc, and Cell Cure Neurosciences Ltd.
Segmentation
The global cerebral palsy market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into spastic cerebral palsy, dyskinetic cerebral palsy, hypotonic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy.
The market, by diagnosis, has been segmented into imaging tests and others. The imaging tests have been further segmented into magnetic resonance imaging (MRI), cranial ultrasound, computed tomography, and electroencephalogram.
The market, by treatment, has been segmented into therapy, medication, surgery, and others. The therapy segment has been segmented into nutrition therapy, hyperbaric oxygen therapy, occupational therapy, physical therapy, stem cell therapy, and others. The medication segment has been segmented into anti-convulsant drugs, muscle relaxants, anti-depressant drugs, anti-inflammatory drugs, and others. Further, the surgery segment has been segmented into orthopedic surgery and others.
Posted by at No comments:
Subscribe to: Posts (Atom)